Do analysts rate SLSN or YSG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Yatsen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SLSN or YSG?

Solesence has higher earnings, but lower revenue than Yatsen. Solesence is trading at a lower price-to-earnings ratio than Yatsen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solesence $62.06M 1.08 $1.79M -$0.03 N/A Yatsen $614.62M 0.47 -$11.56M -$0.21 N/A

Is SLSN or YSG more profitable?

Yatsen has a net margin of -3.04% compared to Solesence's net margin of -3.40%. Yatsen's return on equity of -4.54% beat Solesence's return on equity. Company Net Margins Return on Equity Return on Assets Solesence -3.40% -11.58% -3.79% Yatsen -3.04% -4.54% -3.49%

Does the media prefer SLSN or YSG?

In the previous week, Solesence and Solesence both had 2 articles in the media. Solesence's average media sentiment score of 0.93 beat Yatsen's score of 0.50 indicating that Solesence is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solesence 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yatsen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLSN or NATR?

Nature's Sunshine Products has a consensus price target of $30.50, indicating a potential upside of 114.64%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, analysts clearly believe Nature's Sunshine Products is more favorable than Solesence. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nature's Sunshine Products 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media prefer SLSN or NATR?

In the previous week, Nature's Sunshine Products had 1 more articles in the media than Solesence. MarketBeat recorded 3 mentions for Nature's Sunshine Products and 2 mentions for Solesence. Nature's Sunshine Products' average media sentiment score of 1.86 beat Solesence's score of 0.93 indicating that Nature's Sunshine Products is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solesence 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nature's Sunshine Products 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate SLSN or NAGE?

Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 214.08%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Solesence. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media refer more to SLSN or NAGE?

In the previous week, Niagen Bioscience had 3 more articles in the media than Solesence. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for Solesence. Solesence's average media sentiment score of 0.93 beat Niagen Bioscience's score of 0.62 indicating that Solesence is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solesence 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SLSN or USNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 USANA Health Sciences 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SLSN or USNA?

In the previous week, Solesence and Solesence both had 2 articles in the media. Solesence's average media sentiment score of 0.93 beat USANA Health Sciences' score of 0.77 indicating that Solesence is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solesence 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive USANA Health Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SLSN or NUS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nu Skin Enterprises 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Solesence (SLSN) Competitors

$0.95 0.00 (-0.51%)

As of 08/28/2026 04:00 PM Eastern

Compare

SLSN vs. YSG, NATR, NAGE, USNA, and NUS

Should you buy Solesence stock or one of its competitors? Solesence's main competitors and comparable companies include Yatsen (YSG), Nature's Sunshine Products (NATR), Niagen Bioscience (NAGE), USANA Health Sciences (USNA), and Nu Skin Enterprises (NUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Solesence compare to Yatsen?

Solesence (NASDAQ:SLSN) and Yatsen (NYSE:YSG) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, Solesence and Solesence both had 2 articles in the media. Solesence's average media sentiment score of 0.93 beat Yatsen's score of 0.50 indicating that Solesence is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solesence	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yatsen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Yatsen has a net margin of -3.04% compared to Solesence's net margin of -3.40%. Yatsen's return on equity of -4.54% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Yatsen	-3.04%	-4.54%	-3.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Yatsen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Solesence has higher earnings, but lower revenue than Yatsen. Solesence is trading at a lower price-to-earnings ratio than Yatsen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.08	$1.79M	-$0.03	N/A
Yatsen	$614.62M	0.47	-$11.56M	-$0.21	N/A

Solesence has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Yatsen has a beta of -1.55, suggesting that its stock price is 255% less volatile than the broader market.

70.2% of Solesence shares are held by institutional investors. 4.8% of Solesence shares are held by company insiders. Comparatively, 29.0% of Yatsen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Solesence and Yatsen tied by winning 6 of the 12 factors compared between the two stocks.

How does Solesence compare to Nature's Sunshine Products?

Solesence (NASDAQ:SLSN) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Nature's Sunshine Products has a consensus price target of $30.50, indicating a potential upside of 114.64%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, analysts clearly believe Nature's Sunshine Products is more favorable than Solesence.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nature's Sunshine Products	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Nature's Sunshine Products had 1 more articles in the media than Solesence. MarketBeat recorded 3 mentions for Nature's Sunshine Products and 2 mentions for Solesence. Nature's Sunshine Products' average media sentiment score of 1.86 beat Solesence's score of 0.93 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solesence	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nature's Sunshine Products	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nature's Sunshine Products has a net margin of 3.68% compared to Solesence's net margin of -3.40%. Nature's Sunshine Products' return on equity of 12.88% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Nature's Sunshine Products	3.68%	12.88%	8.17%

Nature's Sunshine Products has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.08	$1.79M	-$0.03	N/A
Nature's Sunshine Products	$480.14M	0.52	$19.52M	$1.01	14.07

Solesence has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

70.2% of Solesence shares are held by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are held by institutional investors. 4.8% of Solesence shares are held by company insiders. Comparatively, 3.1% of Nature's Sunshine Products shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Nature's Sunshine Products beats Solesence on 13 of the 16 factors compared between the two stocks.

How does Solesence compare to Niagen Bioscience?

Solesence (NASDAQ:SLSN) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Niagen Bioscience had 3 more articles in the media than Solesence. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for Solesence. Solesence's average media sentiment score of 0.93 beat Niagen Bioscience's score of 0.62 indicating that Solesence is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solesence	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.08	$1.79M	-$0.03	N/A
Niagen Bioscience	$129.42M	2.02	$17.38M	$0.18	18.28

70.2% of Solesence shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 4.8% of Solesence shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Niagen Bioscience has a net margin of 12.39% compared to Solesence's net margin of -3.40%. Niagen Bioscience's return on equity of 17.95% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Niagen Bioscience	12.39%	17.95%	13.17%

Solesence has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 214.08%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Solesence.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Niagen Bioscience beats Solesence on 15 of the 17 factors compared between the two stocks.

How does Solesence compare to USANA Health Sciences?

Solesence (NASDAQ:SLSN) and USANA Health Sciences (NYSE:USNA) are both small-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

70.2% of Solesence shares are held by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are held by institutional investors. 4.8% of Solesence shares are held by company insiders. Comparatively, 0.8% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

USANA Health Sciences has a net margin of -2.43% compared to Solesence's net margin of -3.40%. USANA Health Sciences' return on equity of 3.41% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
USANA Health Sciences	-2.43%	3.41%	2.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
USANA Health Sciences	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Solesence has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

USANA Health Sciences has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.08	$1.79M	-$0.03	N/A
USANA Health Sciences	$925.26M	0.28	$10.76M	-$1.21	N/A

In the previous week, Solesence and Solesence both had 2 articles in the media. Solesence's average media sentiment score of 0.93 beat USANA Health Sciences' score of 0.77 indicating that Solesence is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solesence	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
USANA Health Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solesence and USANA Health Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Solesence compare to Nu Skin Enterprises?

Solesence (NASDAQ:SLSN) and Nu Skin Enterprises (NYSE:NUS) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Solesence had 2 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 2 mentions for Solesence and 0 mentions for Nu Skin Enterprises. Solesence's average media sentiment score of 0.93 beat Nu Skin Enterprises' score of 0.00 indicating that Solesence is being referred to more favorably in the media.

Company	Overall Sentiment
Solesence	Positive
Nu Skin Enterprises	Neutral

Nu Skin Enterprises has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than Nu Skin Enterprises, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.08	$1.79M	-$0.03	N/A
Nu Skin Enterprises	$1.49B	0.16	$160.20M	-$4.47	N/A

Solesence has a net margin of -3.40% compared to Nu Skin Enterprises' net margin of -15.73%. Nu Skin Enterprises' return on equity of 6.58% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Nu Skin Enterprises	-15.73%	6.58%	3.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nu Skin Enterprises	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Solesence has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

70.2% of Solesence shares are owned by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are owned by institutional investors. 4.8% of Solesence shares are owned by insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Solesence beats Nu Skin Enterprises on 7 of the 13 factors compared between the two stocks.

Get Solesence News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLSN vs. The Competition

Export

Metric	Solesence	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$67.11M	$23.56B	$15.93B	$12.91B
Dividend Yield	N/A	4.26%	3.20%	11.28%
P/E Ratio	-31.67	19.50	13.61	25.45
Price / Sales	1.08	13.49	263,621.78	93.93
Price / Cash	24.94	29.09	57.57	53.00
Price / Book	5.00	2.97	4.47	6.14
Net Income	$1.79M	$1.13B	$838.96M	$348.86M
7 Day Performance	N/A	1.14%	1.43%	-0.80%
1 Month Performance	15.85%	3.50%	0.66%	4.13%
1 Year Performance	-74.04%	-17.86%	12.81%	15.17%

Solesence Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLSN Solesence	0.5208 of 5 stars	$0.95 -0.5%	N/A	-74.0%	$67.11M	$62.06M	N/A	60	News Coverage
YSG Yatsen	0.9729 of 5 stars	$3.00 +0.7%	N/A	-67.2%	$279.54M	$614.62M	N/A	1,623	Short Interest Decrease
NATR Nature's Sunshine Products	4.0047 of 5 stars	$14.34 +0.1%	$30.50 +112.7%	-15.7%	$251.97M	$480.14M	14.20	850	Positive News
NAGE Niagen Bioscience	3.7796 of 5 stars	$3.21 +1.9%	$10.33 +221.9%	-66.8%	$250.88M	$129.42M	17.83	120
USNA USANA Health Sciences	1.6279 of 5 stars	$13.47 +2.2%	N/A	-56.0%	$243.52M	$925.26M	N/A	1,570

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLSN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solesence (SLSN) Competitors

SLSN vs. YSG, NATR, NAGE, USNA, and NUS

How does Solesence compare to Yatsen?

Summary

How does Solesence compare to Nature's Sunshine Products?

Summary

How does Solesence compare to Niagen Bioscience?

Summary

How does Solesence compare to USANA Health Sciences?

Summary

How does Solesence compare to Nu Skin Enterprises?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLSN vs. The Competition

Solesence Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solesence (SLSN) Competitors

SLSN vs. YSG, NATR, NAGE, USNA, and NUS

How does Solesence compare to Yatsen?

Does the media prefer SLSN or YSG?

Is SLSN or YSG more profitable?

Do analysts rate SLSN or YSG?

Which has higher earnings and valuation, SLSN or YSG?

Which has more risk & volatility, SLSN or YSG?

Do insiders & institutionals hold more shares of SLSN or YSG?

Summary

How does Solesence compare to Nature's Sunshine Products?

Do analysts recommend SLSN or NATR?

Does the media prefer SLSN or NATR?

Is SLSN or NATR more profitable?

Which has better earnings & valuation, SLSN or NATR?

Which has more volatility and risk, SLSN or NATR?

Do insiders & institutionals believe in SLSN or NATR?

Summary

How does Solesence compare to Niagen Bioscience?

Does the media refer more to SLSN or NAGE?

Which has stronger valuation & earnings, SLSN or NAGE?

Do institutionals and insiders believe in SLSN or NAGE?

Is SLSN or NAGE more profitable?

Which has more volatility & risk, SLSN or NAGE?

Do analysts rate SLSN or NAGE?

Summary

How does Solesence compare to USANA Health Sciences?

Do insiders & institutionals believe in SLSN or USNA?

Is SLSN or USNA more profitable?

Do analysts rate SLSN or USNA?

Which has more risk & volatility, SLSN or USNA?

Which has higher earnings & valuation, SLSN or USNA?

Does the media prefer SLSN or USNA?

Summary

How does Solesence compare to Nu Skin Enterprises?

Does the media prefer SLSN or NUS?

Which has preferable earnings and valuation, SLSN or NUS?

Is SLSN or NUS more profitable?

Do analysts prefer SLSN or NUS?

Which has more risk & volatility, SLSN or NUS?

Do institutionals and insiders believe in SLSN or NUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLSN vs. The Competition

Solesence Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools